Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where J. Trip is active.

Publication


Featured researches published by J. Trip.


Journal of Neurology, Neurosurgery, and Psychiatry | 2009

Redefining the clinical phenotypes of non-dystrophic myotonic syndromes

J. Trip; Gea Drost; H.B. Ginjaar; F H M Nieman; A.J. van der Kooi; M. de Visser; B.G.M. van Engelen; C.G. Faber

Objective: To redefine phenotypical characteristics for both chloride (ClCh) and sodium channelopathies (NaCh) in non-dystrophic myotonic syndromes (NDM). Methods: In a cross-sectional, nationwide study, standardised interviews and clinical bedside tests were performed in 62 genetically confirmed NDM patients, 32 ClCh and 30 NaCh. Results: Standardised interviews revealed that ClCh reported a higher frequency of muscle weakness (75 vs 36.7%; p<0.01), the warm-up phenomenon (100 vs 46.7%; p<0.001), and difficulties in standing up quickly (90.6 vs 50.0%; p<0.001), running (90.6% vs 66.7; p<0.05) and climbing stairs (90.6 vs 63.3%; p = 0.01). Patients with NaCh reported an earlier onset (4.4 vs 9.6 years; p<0.001), and higher frequencies of paradoxical (50.0 vs 0%; p<0.001) and painful myotonia (56.7 vs 28.1%; p<0.05). Standardised clinical bedside tests showed a higher incidence and longer relaxation times of myotonia in the leg muscles for ClCh (100 vs 60%; mean duration of chair tests 12.5 vs 6.3 s; p<0.001), and in eyelid muscles for NaCh (96.7 vs 46.9%; mean relaxation time of 19.2 vs 4.3 s; p<0.001). Transient paresis was only observed in ClCh (62.5%) and paradoxical myotonia only in NaCh (30.0%). Multivariate logistic regression analyses allowed clinical guidelines to be proposed for genetic testing. Conclusion: This study redefined the phenotypical characteristics of NDM in both ClCh and NaCh. The clinical guidelines proposed may help clinicians working in outpatient clinics to perform a focused genetic analysis of either CLCN1 or SCN4A.


European Journal of Human Genetics | 2008

In tandem analysis of CLCN1 and SCN4A greatly enhances mutation detection in families with non-dystrophic myotonia

J. Trip; Gea Drost; Dennis J Verbove; Anneke J. van der Kooi; Jan B. M. Kuks; Nicolette C. Notermans; Jan J. Verschuuren; Marianne de Visser; Baziel G.M. van Engelen; C.G. Faber; Ieke B. Ginjaar

Non-dystrophic myotonias (NDMs) are caused by mutations in CLCN1 or SCN4A. The purpose of the present study was to optimize the genetic characterization of NDM in The Netherlands by analysing CLCN1 and SCN4A in tandem. All Dutch consultant neurologists and the Dutch Patient Association for Neuromuscular Diseases (Vereniging Spierziekten Nederland) were requested to refer patients with an initial diagnosis of NDM for clinical assessment and subsequent genetic analysis over a full year. Based on clinical criteria, sequencing of either CLCN1 or SCN4A was performed. When previously described mutations or novel mutations were identified in the first gene under study, the second gene was not sequenced. If no mutations were detected in the first gene, the second gene was subsequently also analysed. Underlying NDM mutations were explored in 54 families. In total, 20% (8 of 40) of our probands with suspected chloride channel myotonia showed no CLCN1 mutations but subsequent SCN4A screening revealed mutations in all of them. All 14 probands in whom SCN4A was primarily sequenced showed a mutation. In total, CLCN1 mutations were identified in 32 families (59%) and SCN4A in 22 (41%), resulting in a diagnostic yield of 100%. The yield of mutation detection was 93% with three recessive and three sporadic cases not yielding a second mutation. Among these mutations, 13 in CLCN1 and 3 in SCN4A were novel. In conclusion, the current results show that in tandem analysis of CLCN1 and SCN4A affords high-level mutation ascertainment in families with NDM.


Neuromuscular Disorders | 2015

Myotonic discharges discriminate chloride from sodium muscle channelopathies.

Gea Drost; Bas C. Stunnenberg; J. Trip; George F. Borm; Kevin C. McGill; Ieke B. Ginjaar; Arendina W. van der Kooi; Machiel J. Zwarts; Baziel G.M. van Engelen; Catharina G. Faber; Dick F. Stegeman; Zoia C. Lateva

Non-dystrophic myotonic syndromes represent a heterogeneous group of clinically quite similar diseases sharing the feature of myotonia. These syndromes can be separated into chloride and sodium channelopathies, with gene-defects in chloride or sodium channel proteins of the sarcolemmal membrane. Myotonia has its basis in an electrical instability of the sarcolemmal membrane. In the present study we examine the discriminative power of the resulting myotonic discharges for these disorders. Needle electromyography was performed by an electromyographer blinded for genetic diagnosis in 66 non-dystrophic myotonia patients (32 chloride and 34 sodium channelopathy). Five muscles in each patient were examined. Individual trains of myotonic discharges were extracted and analyzed with respect to firing characteristics. Myotonic discharge characteristics in the rectus femoris muscle almost perfectly discriminated chloride from sodium channelopathy patients. The first interdischarge interval as a single variable was longer than 30 ms in all but one of the chloride channelopathy patients and shorter than 30 ms in all of the sodium channelopathy patients. This resulted in a detection rate of over 95%. Myotonic discharges of a single muscle can be used to better guide toward a molecular diagnosis in non-dystrophic myotonic syndromes.


Cochrane Database of Systematic Reviews | 2006

Drug treatment for myotonia

J. Trip; Gea Drost; Baziel G.M. van Engelen; C. G. Faber


Journal of Neurology | 2007

Warm-up phenomenon in myotonia associated with the V445M sodium channel mutation

J. Trip; C. G. Faber; H.B. Ginjaar; B.G.M. van Engelen; Gea Drost


Neuromuscular Disorders | 2009

G.P.14.10 Clinical experience with acetazolamide treatment in children; good response in both sodium and chloride channelopathies

L.T.L. Sie; Bas C. Stunnenberg; J. Trip; Ieke B. Ginjaar; Gea Drost


Cochrane Database of Systematic Reviews | 2006

Drug treatment for myotonia (Review)

J. Trip; Gea Drost; B.G.M. van Engelen; C. G. Faber


Neuromuscular Disorders | 2007

Genotype-phenotype correlations for the skeletal muscle chloride- and sodium-channelopathies

J. Trip; Gea Drost; Ieke B. Ginjaar; A.J. van der Kooi; Nicolette C. Notermans; J. van Oostrom; J. Verschuuren; M. de Visser; B.G.M. van Engelen


Tijdschrift voor Neurologie en Neurochirurgie | 2006

Twee families met stijve spieren:: de niet-dystrofische myotonieën

J. Trip; Gea Drost; W. H. J. P. Linssen; J. Krudde; B.G.M. B.G.M. van Engelen; C. G. Faber


Nederlands Tijdschrift voor Geneeskunde | 2005

Het spectrum van de erfelijke skeletspierkanalopathieën

J. Trip; Gea Drost; H.B. Ginjaar; Bgm van Engelen; C. G. Faber

Collaboration


Dive into the J. Trip's collaboration.

Top Co-Authors

Avatar

Gea Drost

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

C. G. Faber

Maastricht University Medical Centre

View shared research outputs
Top Co-Authors

Avatar

B.G.M. van Engelen

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ieke B. Ginjaar

Leiden University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bas C. Stunnenberg

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

M. de Visser

University of Amsterdam

View shared research outputs
Researchain Logo
Decentralizing Knowledge